LTC Properties Inc vs Merck & Co., Inc. — how do they compare? LTC Properties Inc trades at $38.12 (market cap $2.05B), while Merck & Co., Inc. trades at $130.04 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 157× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.98%). Which is the better fit depends on your goals.
| LTC | MRK | |
|---|---|---|
Market Cap | $2.05B | $321.77B |
Sector | Real Estate | Health |
52-Week High | $42.81 | $131.84 |
52-Week Low | $33.98 | $77.60 |
Enterprise Value | $2.79B | $368.53B |
Dividend Yield | 5.98% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Trailing returns across standard periods
Latest headlines on both assets
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →